Stephanie Davis
Stock Analyst at Barclays
(0.63)
# 3,942
Out of 5,051 analysts
97
Total ratings
33.82%
Success rate
-105.82%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $190 → $195 | $178.26 | +9.39% | 7 | Oct 22, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $36.75 | +22.45% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $19.16 | -73.90% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $63.99 | +17.21% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $4.81 | +45.53% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $3.33 | +80.18% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $6.35 | +199.21% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $354.00 | -18.08% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $28.15 | -14.74% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $196.79 | -32.42% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $35.74 | +62.28% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $3.44 | -12.79% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $250.69 | -0.67% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $22.67 | +27.92% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $8.06 | +321.84% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $18.88 | +80.08% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $295.26 | -21.09% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.05 | +457.38% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $94.39 | -19.48% | 5 | Jun 7, 2022 |
Quest Diagnostics
Oct 22, 2025
Maintains: Equal-Weight
Price Target: $190 → $195
Current: $178.26
Upside: +9.39%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $36.75
Upside: +22.45%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $19.16
Upside: -73.90%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $63.99
Upside: +17.21%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $4.81
Upside: +45.53%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $3.33
Upside: +80.18%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $6.35
Upside: +199.21%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $354.00
Upside: -18.08%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $28.15
Upside: -14.74%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $196.79
Upside: -32.42%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $35.74
Upside: +62.28%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.44
Upside: -12.79%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $250.69
Upside: -0.67%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $22.67
Upside: +27.92%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $8.06
Upside: +321.84%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $18.88
Upside: +80.08%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $295.26
Upside: -21.09%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.05
Upside: +457.38%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $94.39
Upside: -19.48%